Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science

5131 - Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types

Date

09 Sep 2017

Session

Basic science

Presenters

Laurie Gay

Citation

Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391

Authors

L.M. Gay1, D. Pavlick2, J. Chung3, S. Ramkissoon1, S. Daniel1, J.A. Elvin1, E. Severson1, T. Bivona4, K.L. Reckamp5, S.J. Klempner6, S.I. Ou7, A.B. Schrock1, V.A. Miller1, P.J. Stephens1, J.S. Ross8, S. Ganesan9, C. Lovly10, A. Mansfield11, S.M. Ali1

Author affiliations

  • 1 Pathology, Foundation Medicine, 02141 - Cambridge/US
  • 2 Cancer Genomics, Foundation Medicine, 02141 - Cambridge/US
  • 3 Clinical Development, Foundation Medicine, MA 02141 - Cambridge/US
  • 4 Department Of Medicine, University of California, San Francisco/US
  • 5 Clinical Research Operations, City of Hope, Duarte/US
  • 6 Oncology, The Angeles Clinic, 90025 - Los Angeles/US
  • 7 Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, 92868 - Orange/US
  • 8 Pathology, Albany Medical Center, 12208 - Albany/US
  • 9 Cancer Institute Of New Jersey, Rutgers University, 08903 - New Brunswick/US
  • 10 Department Of Medicine, Vanderbilt University, 37232-6838 - Nashville/US
  • 11 Division Of Medical Oncology, Mayo Clinic, 55905 - Rochester/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5131

Background

Kinase fusions (KFN) are well recognized as targetable drivers in some cancers, and KFN common in one disease can be found in unrelated histologies, as for BRAF. Recently, oncogenic KDD in BRAF and EGFR were reported, along with responses to tyrosine kinase inhibitors (TKI). We assessed the frequency of KDD and KFN across 114,200 advanced cancers to reveal the landscape of oncogenic KFN and non-canonical rearrangements (KRE) in a wide variety of subtypes.

Methods

CGP was performed on DNA and/or RNA from 114,200 solid tumors or heme malignancy samples for 184-406 cancer-related genes and select introns from 14-28 genes commonly rearranged in cancer. RNA sequencing for 265 genes was available for some cases. Selected genomic events were confirmed by manual inspection.

Results

KDD were observed in 598 cases (0.62%): BRAF (127), EGFR (115), FGFR3 (94), FGFR1 (40), RET (37), ERBB2 (35), PDGFRA (35), FGFR2 (28), MET (19), ROS1 (14), ALK (13), KIT (8), NTRK1 (8), FLT3 (6), FGFR4 (5), ERBB4 (4), PDGFRB (3), NTRK2 (2). KDD were seen in 2.7% of brain tumors, most often EGFR (66), BRAF (52), PDGFRA (13), and FGFR3 (26). In extracranial tumors, KDD were common for RET (13-16% of breast, lung, and thyroid KDD+ cases), MET (15-20% of uterine and brain KDD+ cases), and ALK (54% of lung KDD+ cases). KDD possibly related to TKI resistance were seen in BRAF V600E-positive melanoma and ALK-related NSCLC. Table 1 summarizes KFE and KFN for ALK, FGFR2/3, RET, and ROS1; 48-57 tumor types are affected per gene. KFN partner varied by tumor site; for ROS1, GOPC KFN predominate in gliomas and CRC, TFG KFN in sarcomas, and CD74 and EZR in NSCLC.Table:

1700O

ALKFGFR2FGFR3RETROS1
All SamplesFNREFNREFNREFNREFNRE
NSCLC2086859076105325240301897
Brain631737282531246
Pancreatobiliary79348117850727525
Bladder1458139102
Thyroid972523821
All Other766511322712265891471343853

Conclusions

KDD are enriched in brain tumors. Diverse KDD are found extracranially and may underlie acquired resistance. Index cases with clinical responses to matched TKIs suggest KDD, KFN and KRE can be targeted therapeutically in many histological subtypes. Recurrent KFN are found widely in cancer, with gene partner varying by subtype.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine

Funding

Foundation Medicine

Disclosure

L.M. Gay, S. Ramkissoon, S. Daniel, J.A. Elvin, E. Severson, A.B. Schrock, V.A. Miller, P.J. Stephens, J.S. Ross, S.M. Ali: An employee of and stockholder in Foundation Medicine, Inc. D. Pavlick, J. Chung: Employee of and shareholder in Foundation Medicine, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.